B2M and pancreatic ductal adenocarcinoma: B2M overexpression is correlated with a poor prognosis in several human cancers, including pancreatic ductal adenocarcinoma[41–43] and it has been considered as a potential target for cancer therapy.[41,42] Consistently, we found that CXCL10, CD44, B2M, XRCC5, PTPN11, and RPL11 were upregulated in the LA-NPC tumors with metastasis compared with tumors without metastasis, and genes CD44, B2M, PTPN11, and RPL11 were associated with the DFS in NPC patients in the GSE102349 dataset.